Speciality Restaurants Ltd Share Price

Overview

Speciality Restaurants Ltd share price is currently ₹132.40, down by - ₹0.44 (0.33%) from its previous closing price of ₹132.84. The share price has declined -15.75% over the past month and gained 7.48% over the past year. The stock's 52-week low and high are ₹81.58 and ₹166.48, respectively. Speciality Restaurants Ltd has a market capitalisation of ₹ 670.00 Cr. The share price was last updated on 09 Sep 2026, 03:28 PM IST.

Speciality Restaurants Ltd
Speciality Restaurants Ltd
SPECIALITY
 0.00
- 0.44
0.33%
Hospitality
 0.00(%)1D

Updated: 09 Sep 2026, 03:28:53 pm IST

Market Data

Open Price

 131.84

Prev. Close

 132.84
 128.84

Day Low

 133.42

Day High

 81.58

52 Week Low

 166.48

52 Week High

HospitalityRestaurants
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

27.24

Sector PE

35.29

PB Ratio

1.84

Sector PB

4.54

EPS

4.86

Dividend Yield

1.19

Today's Volume

17.330 K

5 Day Avg. Volume

16.893 K

PEG Ratio

55.59

Market Cap.

₹ 670.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 10% at ₹1/Share
04-Sep-202604-Sep-2026
DividendsFinal Dividend of 10% at ₹1/Share
28-Aug-202528-Aug-2025
DividendsFinal Dividend of 10% at ₹1/Share
13-Sep-202414-Sep-2024

Mutual Fund Ownership

Mutual Fund Ownership will be available shortly.

About Speciality Restaurants Ltd 👋

Speciality Restaurants Limited is an India-based company. The Company is primarily engaged in the business of operating casual dining restaurants outlets and confectionary outlets. The Company has a chain of fine dining, casual dining, bar and lounge and bakery and confectionery outlets and restaurants all over the country. It operates approximately 129 restaurants and confectioneries in 25 cities in India, Dhaka (Bangladesh), Dar-es-Salaam (Tanzania), Colombo (Sri Lanka) and Dubai (United Arab Emirates). Its brands include Mainland China, Oh! Calcutta, Asia Kitchen By Mainland China, Sigree, Sigree Global Grill, Spicery by Sigree, Jungle Safari, Urban Deccan Pub, Hoppipola, Hay, Episode One, Gong Modern Asia, Sweet Bengal, Cafe Mezzuna, Flame & Grill, Haka, Machaan, Dariole, Zoodles, and Speciality Catering Services. Mainland China operates approximately 23 outlets across 10 cities in India, including Mumbai, Pune, Kolkata, Bhubaneshwar, Chennai, Bangalore, Hyderabad, and Ahmedabad.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Akhilesh Jat SEBI RA

Akhilesh Jat SEBI RA

9 Sep • 9:10 AM · SEBI-Registered Analyst

Laxmi Organic Industries in Focus After CEO Transition News

Laxmi Organic Industries stock may remain in focus on September 9 after Rajan Venkatesh resigned as MD & CEO. Harshvardhan Goenka will take charge from November 14, 2026. Laxmi Organic Industries Ltd. (NSE:

LXCHEM
) is likely to remain in focus in today’s trading session, September 9, 2026, following a key leadership change announced by the company. Rajan Venkatesh has resigned as Managing Director and Chief Executive Officer (MD & CEO), effective November 13, 2026, to pursue opportunities outside the company. The Board has appointed Executive Director Harshvardhan Goenka as the new MD & CEO for a five-year term, effective November 14, 2026. The development comes as the stock has faced pressure over the past year. LXCHEM closed at ₹184.52 on September 8, 2026, down more than 19% over the last one year. The stock currently trades within a 52-week range of ₹108–₹241. Laxmi Organic Industries operates in acetyl and specialty intermediates, serving pharmaceuticals, agrochemicals, paints, and other industries. Investors may track management commentary and the market’s reaction to the leadership transition in today’s session. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More
AASHISH RA

AASHISH RA

8 Sep • 10:26 PM · SEBI-Registered Analyst

GRANULES INDIA —pharmaceutical company Finished Dosages (FD)

GRANULES
Strengths Strong FY26 growth: Consolidated revenue from operations increased 20% YoY to ₹5,365.6 Cr. Profitability improved: FY26 EBITDA rose 25% to ₹1,185.1 Cr, while PAT increased 19% to ₹595.0 Cr. Vertically integrated model across API → PFI → Finished Dosage provides greater control over manufacturing and supply chain. Diversified product portfolio: Core molecules include Paracetamol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol, alongside newer API and CDMO businesses. Weaknesses North America remains the largest market, creating geographical concentration risk despite improving diversification. The business has meaningful exposure to generic-drug pricing pressure. Pharmaceutical manufacturing requires continuous investment in regulatory compliance, quality systems and capacity. Opportunities CDMO/CRAMS expansion can create a higher-value growth engine beyond the traditional generic business. Increasing demand for complex generics and specialty pharmaceuticals can support margin expansion. The company's peptide platform provides an opportunity to participate in a rapidly growing pharmaceutical segment. Europe is showing strong momentum, offering potential for further geographical diversification. Threats U.S. FDA/regulatory risk remains important because of the company's significant exposure to regulated markets. Generic-drug price erosion and intense competition can pressure margins. Dependence on North America makes the company sensitive to U.S. healthcare-policy and pricing changes. Raw-material costs, currency movements and supply-chain disruptions can affect profitability. Competition in CDMO, peptides and complex generics could require substantial continuing R&D expenditure. Delays in regulatory approvals or commercialization of new products could affect expected growth.

See More
Naveen Kumar

Naveen Kumar

8 Sep • 4:10 PM · SEBI-Registered Analyst

Prasol Chemicals IPO Positives and Negatives

Does stock fall in these catagories?: Growth / New Product Growth: The company is showing strong revenue growth 20% CAGR and net profits have doubled, indicating a scaling business model. Capacity Expansion: The company is consistently increasing its installed capacity and maintains high capacity utilization, showing operational momentum. Strong Brand / Relationship: 93% of revenue comes from repeat customers, reflecting deep, long-term relationships and product stickiness in the specialty chemicals market. Debt Management: Unlike peers who load up on debt to expand, Prasol is funding its growth largely through internal accruals and profits. Efficient Asset Base: Most manufacturing facilities are either owned or held on extremely long-term leases 90 years, providing operational stability. Key Risks Discussed: Aggressive IPO Structure: A significant portion of the IPO is an Offer for Sale OFS, meaning money is going to promoters' pockets rather than into the business, which limits future value creation for new investors. Aggressive Valuation: The company is coming in at a P/E ratio of 50, significantly higher than industry peers, leaving little room for listing gains. Working Capital Issues Trade Receivables: A concerning trend where profit is being "locked up" in trade receivables uncollected payments rather than translating into hard cash flow. Macroeconomic Sensitivity: The business is subject to global crude oil price volatility and geopolitical tensions, which impact chemical feedstock costs. Corporate Restructuring: Recent changes in corporate structure make predicting future performance difficult until fresh, post-restructuring quarterly results are released.

See More
Mohammed Shoaib

Mohammed Shoaib

8 Sep • 8:37 AM · SEBI-Registered Analyst

Nifty Pharma | The Only Sector That Ended Green on Sept 7

Sector performance, Monday September 7, 2026: Nifty IT: declined. Nifty Metal: declined. Nifty PSU Bank: declined. Nifty Media: declined. Nifty Auto: declined. Nifty FMCG: declined. Nifty Private Bank: declined. Nifty Realty: declined. Nifty Financial Services: declined. Nifty Pharma: the sole sectoral index to close in the green on the NSE. That single-line summary of Monday's session captures the defensive rotation that has now repeated itself in every major sell-off session of August and September 2026. When geopolitical tension escalates, crude rises, bond yields spike and the Nifty falls — the market's one consistent buyer is pharmaceutical stocks. The logic is structural. Pharmaceutical demand is inelastic — a patient requiring Sun Pharma's specialty drug or

DRREDDY
biosimilar does not delay treatment because Brent crude is trading at $91 per barrel. For companies with significant US revenue exposure, a weaker rupee driven by rising crude and dollar strengthening actually improves rupee-denominated export earnings without any change in underlying demand. The combination of defensive demand and currency tailwinds makes pharma the most reliable single-sector bid in every crude-driven market downturn. The Nifty 50 closed Monday at 23,779.15, down 118.55 points. The Nifty MidCap declined 0.46 per cent. The Nifty SmallCap rose 0.02 per cent. And Nifty Pharma closed higher — for the fourth time in five major down-day sessions since August 19.

See More
THREETREND RESEARCH

THREETREND RESEARCH

7 Sep • 9:54 PM · SEBI-Registered Analyst

Hindalco Industries has reported a very strong Q1 FY27

HINDALCO
Hindalco Industries has reported a very strong Q1 FY27, with consolidated revenue rising 32% YoY to ₹84,825 crore, EBITDA jumping 73% to ₹14,989 crore, and PAT increasing 75% to a record ₹7,013 crore. The India aluminium business delivered record performance, while Novelis EBITDA increased 37%, helped by the restart of the Oswego hot mill and cost-optimisation measures. Another positive trigger is Hindalco's aggressive ₹50,000-crore investment pipeline across aluminium, copper and recycling; management expects consolidated net debt to peak around ₹80,000 crore as these projects are executed, so capex-led growth comes with higher leverage risk. The company is also expanding its specialty alumina portfolio, recently commissioning a 30,000-tonne-per-year precipitated aluminium trihydrate facility in Belagavi, with scope to double capacity, targeting applications such as fire safety, wires and cables and EVs. Hindalco's Bay Minette project in the US is moving through commissioning, while the Oswego plant is ramping up, which could improve Novelis' performance further. On the risk side, the company remains exposed to global aluminium/copper prices, Novelis execution, higher debt due to capex and global trade/regulatory changes; notably, the EU is considering restrictions on aluminium-scrap exports to non-OECD countries, which could affect recycling-related supply chains. Overall, record Q1 earnings, Novelis recovery, strong aluminium/copper performance and large downstream expansion projects are major positive triggers, while leverage and commodity-cycle volatility remain key risks.

See More
Pyrifera Investment Advisors

Pyrifera Investment Advisors

7 Sep • 5:32 PM · SEBI-Registered Analyst

Jayaswal Neco Industries Clarifies Zero Link to Datasel SRL

Jayaswal Neco Industries Limited has issued a formal clarification stating it has no corporate or financial relationship with Datasel SRL, the Italian-registered firm at the center of a botched €70 million European arms procurement deal. Key Highlights: No Corporate Link: The listed entity confirmed it had zero subsidiary or associate companies in FY26, completely distancing itself from Datasel SRL. Zero Financial Impact: The company faces no financial liability from the controversy. FY26 standalone turnover stood at a robust ₹7,131.82 crore, with exports contributing a negligible 0.38% (₹27.08 crore). Promoter-Level Separation: Datasel SRL is owned by Neco Defence Munitions, a promoter-level entity that operates entirely outside the listed company’s corporate structure. Strategic & Market Implications: Effective Risk Mitigation: This clarification is a crucial corporate governance measure. It successfully ring-fences the listed steelmaker from the geopolitical and legal fallout surrounding the European contract (which recently led to the resignation of Estonia’s Defence Minister). Investor Confidence: While minor short-term volatility due to brand association is possible, the company’s core business remains firmly rooted in domestic specialty steel and castings. Public shareholders are fully insulated from the promoter group's private defense disputes, ensuring the listed entity's balance sheet and operations remain unaffected.

JAYNECOIND

See More

Frequently Asked Questions

What is the share price of Speciality Restaurants Ltd?

What is the market cap of Speciality Restaurants Ltd?

Should I buy Speciality Restaurants Ltd stock now?

What is the 52 week high and low of Speciality Restaurants Ltd?

Is the Speciality Restaurants Ltd stock good to buy?

Is Speciality Restaurants Ltd a good buy for the long term?

Is Speciality Restaurants Ltd overvalued or undervalued?

What is the PE and PB ratio of Speciality Restaurants Ltd?

Start Now